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Abstract
Continuous vancomycin has been previously reported to maximize antimicrobial
activity while avoiding toxicities associated with dose escalation, but the efficacy of
this dosing strategy has not been reported. This case report describes the successful
use of continuous vancomycin, including improvement in lung function and avoidance
of nephrotoxicity, demonstrated in a pediatric cystic fibrosis (CF) patient with MRSA.
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1 | BACKGROUND
Vancomycin is a glycopeptide antibiotic that is effective against gram-
positive organisms, including methicillin-resistant Staphylococcus aureus
(MRSA). Based on its time-dependent antimicrobial activity, maximal
bactericidal effects occur when the concentration of vancomycin remains
significantly above the bacterial minimum inhibitory concentration (MIC).
However, targeting higher peak concentrations to maximize time above
MIC is associated with more adverse effects, such as nephrotoxicity.
Continuous vancomycin therapy has been previously reported tomaximize
the antimicrobial effects of vancomycin while avoiding the toxicities
associatedwithdoseescalationandelevatedpeakconcentrations, although
the efficacy of this approach was not reported.1 Here we describe the
successful use of continuous vancomycin in a pediatric cystic fibrosis (CF)
patient with MRSA who had a significant drug allergy profile.
2 | CASE
A 12-year-old girl with CF was admitted to the inpatient pediatric
pulmonary service for treatment of a CF pulmonary exacerbation.
Her pulmonary function tests (PFTs) on admission were percent
predicted (pp) FVC 81, ppFEV1 79%, ppFEF25-75 77%, as compared
to her best PFTs in the past year of ppFVC 110, ppFEV1 105, and
ppFEF25-75 100. Since presenting to our CF center one and a half
years prior, the patient has had three bronchoscopy cultures and 12
sputum cultures obtained. Of these, two bronchoscopies were
positive for MRSA only, and the third grew MRSA and mold. Of the
sputum cultures, eight grew only MRSA, and another (the first
obtained at our center) grew Pseudomonas in addition to MRSA.
Given thishistoryof infectionprimarilywithMRSA,prior toadmission
she was treated with a 3 week course of tedizolid directed against MRSA
as her typical respiratory pathogen. On week prior to admission oral
minocycline was added to her antibiotic regimen. She underwent
bronchoscopy upon admission to determine if there were any other
pathogens present that could account for her failure to respond to
tedizolid, but cultures only grew 800 000CFU/mL of MRSA. The patient
has multiple allergies and reactions to medications that complicated
antibiotic management, including significant hives with both minocycline
and ceftaroline, independent of one another; facial swelling with
aztreonam; paresthesias with linezolid during two treatment courses;
andsignificant redmansyndromewith intermittentdosingofvancomycin.
Hermost recent culture susceptibilities indicatedsensitivity toceftaroline,
doxycycline, linezolid, and vancomycin (with a MIC of 2mcg/mL) and
resistance to clindamycin and sulfamethoxazole/trimethoprim.
Upon admission she was started on IV minocycline, however, she
developed hives. The pediatric allergy service was consulted and they
determined that she was having a delayed hypersensitivity reaction to
minocycline, therefore it was discontinued. Given this patient's numerous
drug allergies and reactions, the decision was made to treat her pulmonary
exacerbation with vancomycin, utilizing a longer infusion time of 2 h and
premedication with diphenhydramine 25mg to minimize reaction. Despite
these interventions, thepatientcontinuedtoexperience intolerable redman
symptoms, which did not resolve by increasing the infusion time to 3h and
diphenhydramine dose to 50mg. After 3 days, she was started on
continuous vancomycin, with a goal concentration of 20-25mcg/mL. The
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patient was initiated on 3000mg over 24h (64mg/kg), and a level was
obtained the followingmorning, about 22.5 h after the start of the infusion
(Table 1). The patient remained in the hospital for five additional days after
starting the continuous vancomycin, during which time one dose
adjustment was made (Table 1). Prior to discharge, her repeat PFTs
demonstrated significant improvement in her lung function to ppFEV1 103.
She was discharged home, where she completed an additional 5 days of
continuous vancomycin before discontinuing vancomycin due to develop-
ment of hives on her lower extremities. No changes in renal function were
observed, and the patient felt that the redman symptoms she experienced
were tolerable with diphenhydramine 25mg as needed.
3 | DISCUSSION
The evidence supporting the use of continuous vancomycin is limited. The
majority of studies evaluating continuous vancomycin are in adult patients,
andmostevaluatenephrotoxicityandadverseeffects, asopposed toclinical
efficacy, as the primary endpoint.2–3 These previous studies have
demonstrated that continuous vancomycin does not result in an increased
incidence of nephrotoxicity, and in some studies, the incidence was
significantly less when compared to intermittent vancomycin.
In2012,McKamyetal,1 describedadosingguideline that converted
pediatric patients at a single institution from intermittent vancomycin
dosing to continuous vancomycin for patientswho had two consecutive
subtherapeutic trough concentrations. Patients had to have either
pneumonia or osteomyelitis due to gram-positive organisms, including
MRSA. The authors found fewadverse effects associatedwhenpatients
were transitioned to continuous vancomycin, including nephrotoxicity.
This study did not report patient outcomes.
In our patient, it is interesting to note that she tolerated
continuous vancomycin despite her significant red man syndrome
with intermittent dosing. Given that red man syndrome is typically
associated with rapid infusion of vancomycin, it is reasonable to
consider that the slower continuous infusion may be more tolerable.4
Our patient's case demonstrates successful use of continuous
vancomycin in a pediatric CF patient with significant drug allergies related
to antimicrobials targeting her MRSA, as well as resistance limiting
therapeutic options. In addition to achieving therapeutic vancomycin
concentrations from the beginning of therapy, our patient also had no
nephrotoxicity, as assessed by serum creatinine, associated with the
continuous vancomycin and had a significant improvement in PFTs,
demonstrating efficacy of this dosing regimen.
CONFLICTS OF INTEREST
The views expressed in this article do not communicate an official
position of the University of North Carolina Medical Center or
University of North Carolina School of Medicine.
ORCID
Cameron J. McKinzie http://orcid.org/0000-0003-1401-5628
Charles R. Esther http://orcid.org/0000-0002-8081-2986
REFERENCES
1. McKamy S, Chen T, Lee M, Ambrose PJ. Evaluation of a pediatric
continuous-infusion vancomycin guideline. Am J Health-Syst Pharm.
2012;69:2066–2071.
2. Man SSK, Carr RR, Ensom MHH. Comparison of continuous and
intermittent IV infusion of vancomycin: systematic review. Can J Hosp
Pharm. 2010;63: 373–381.
3. DiMondi VP, Rafferty K. Review of continuous-infusion vancomycin.
Ann Pharmacother. 2013;47:219–227.
4. Wallace MR, Mascola JR, Oldfield EC. Red man syndrome: incidence,
aetiology and prophylaxis. J Infect Dis. 1991;164:1180–1185.
How to cite this article: McKinzie CJ, Esther CR, Vece TJ.
Continuous vancomycin in a pediatric cystic fibrosis patient.
Pediatric Pulmonology. 2018;53:E4–E5.
https://doi.org/10.1002/ppul.23844
TABLE 1 Laboratory values and clinical decision making
Day BUN (mg/dL) SCr (mg/dL)
Vancomycin
concentration (μg/mL) Action taken
1 10 0.42 - -
8 11 0.45 25.4 Continued same dose
9 - - 27.7 Decreased dose to 2500mg/day
(53mg/kg)
10 10 0.46 21.8 Continued same dose
11 8 0.46 23.2 Continued same dose
14a 10 0.45 - -
15a - - 22.3 Continued same dose
aThese labs were obtained while the patient was outpatient.
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